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ABSTRACT 
A retrospective review of 30 patients with eso/exodeviations less than 20 prism diopters (PD) who 
underwent one injection of BPX into their medial/lateral rectus was carried out. Preoperative deviations 
were recorded in PD, using the alternate prism cover test. Postoperative angles at 1 and 3 months were 
measured in the same manner. 11 out of 30 patients achieved an acceptable outcome and required no 
further intervention. 
The mean angle of deviation for near in all patients reduced significantly by 3.1 PD and 2.1 PD at 1 and 3 
months. The mean angle of deviation for distance in all patients also decreased significantly by 2.3 PD and 
1.9 PD at 1 and 3 months. In conclusion, single injection of BPX in a heterogeneous group of patients with 
horizontal strabismus caused a mild improvement and a qualitative success rate of 37%. 
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INTRODUCTION 
Bupivacaine hydrochloride (BPX) is a sodium channel 
blocker local anesthetic that also displaces calcium from 
membrane binding sites and increases cytoplasmic Ca2+ 
level. This results in a particular myotoxixcity that leaves 
the basal lamina, satellite cells, nerve fibers and vessels 
intact allowing regeneration of muscle fibers (1, 2). 
Unintentional injection of BPX into the extraocular 
muscles during the local anesthesia for cataract surgery 
can cause strabismus due to muscle hypertrophy and 
increased stiffness (3-5). 
Scott et al showed for the first time that the injection of 
BPX into the lateral rectus corrected esotropia in 4 of 6 
patients. The average improvement in alignment for all 
patients was 8 PD, with associated 6.2% increase in 
muscle volume measured from MRI images. Later they 
reported an average improvement of 19.7 PD in 
alignment when treated the affected muscle with BPX 
and its antagonist with botulinum type A toxin (6-8). 
Hopker et al reported an average improvement of 10 PD 
after six months using combination of BPX and botulinum 
toxin in eight patients (9). More recently, Miller et al 
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have shown lasting changes in alignment and extraocular 
muscle shape after injection of BPX alone or in 
combination with botulinum toxin in concomitant non-
paralytic strabismus (10). 
 We report the outcome of a single injection of BPX for 
correction of small angle (<20 PD) horizontal strabismus 
in a heterogeneous group of patients. 
 
METHODS 
This is a retrospective review of all patients injected with 
BPX at a referral center in Liverpool, UK, from March 
2008 to February 2013. Eventually, this study included 
thirty (15 male, 15 female) patients with horizontal 
strabismus. Four additional patients also received BPX 
injection but were lost to follow- up after injection and 
therefore not included in this report. BPX was injected 
into their lateral (LR) or medial rectus (MR) muscle, 
depending on diagnosis. This method has been part of 
the standard management of patients with small angle 
deviation (≤ 20 PD) and in those with multiple previous 
surgeries who preferred a non-surgical alternative for 
small residual deviations. 
Institutional audit approval was obtained. Marcaine 
(AstraZeneca, Bedfordshire, UK) - bupivacaine 
hydrochloride injection containing 0.5 g/dl bupivacaine, 
in individual dose of 4.5 to 5 ml was injected into the LR 
or MR under topical anesthesia (Minims® Oxybuprocaine 
Hydrochloride 0.4% w/v, Bausch & Lomb, Kingston-upon-
Thames, UK) using a special needle insulated apart from 
the bevel and electromyography from the bevel. Maximal 
electrical signal indicated the area of greatest density of 
neuromuscular junctions and at that point the BPX was 
injected. A single surgeon (I.B.M) carried out all 
injections. 
Preoperative measurements of the horizontal deviations 
of all patients were recorded in PD, using the alternate 
prism cover test at both 1/3 meter and 6 meters for all 
patients. Postoperative deviations were measured in the 
same manner at 1 and 3 months. 
The following information were recorded as much as 
possible; age at presentation, best corrected visual 
acuity, diagnosis, detail of previous surgery and 
chemodenervation, sensory status, angle of deviation 
before and at 1 and 3 months after injection, outcome 
and complications. Patients with thyroid eye disease 
were excluded. 
Values of angle of deviation are given as mean+/- 
standard deviation (95% confidence interval). Repeated 
Measures ANOVA and Wilcoxon paired test were 
employed to assess the comparison of the angle of 
deviation before or 1 and 3 months after the injection. P 
values less than 0.05 are considered significant. 
Graphpad prism 6 (Graphpad Software, Inc. La Jolla, CA, 
USA) was used for statistical analysis. 
 
RESULTS 
The age distribution of our patients was between 20 and 
81 years with a mean of 43.4 (median = 40). The average 
visual acuity was 0.1 (range: 0.2 to 1.0) LogMAR. Five 
patients had visual acuity worse than 0.8 LogMAR in the 
deviating eye. 
Sixteen patients (seven females and nine males) with 
esotropia underwent one injection of BPX into their LR, 
(right: 8, left:8). Their average age was 44 (range: 24–81) 
years. Eight patients had previous surgery on their LR and 
were left with small angle residual esotropia, two had 
residual esotropia following recovery from abducens 
nerve palsy. None had chemodenervation of LR but three 
had previous MR chemodenervation. 
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Table 1.  Comparison of the mean angle of deviations 
among the groups 
 Pre-
op 
 
1 
month 
 
3 
months 
Change 
at 1m 
Change 
at 3 m 
Esodeviation 
n=16 
Distance 
ANOVA 
P=0.008 
9.6 7.1 
 
7.5 
 
 
2.5 2.1 
Near 
ANOVA 
p>0.05 
9.9 7.6 
 
8.3 
 
2.3 1.6 
 
Exodeviation 
n=14 
Distance 
ANOVA 
P>0.05 
7.9 5.9 
 
6.2 
 
2.0 1.7 
Near 
ANOVA 
p=0.06 
11.3 7.1 
 
8.6 
 
 
4.2 2.7 
Combined 
n=30 
Distance 
ANOVA 
P<0.05 
8.8 
 
6.5 
 
 
6.9 
 
 
2.3 1.9 
Near 
ANOVA 
P<0.05 
10.5 
 
7.4 
 
 
8.4 3.1 2.1 
 
The average preoperative distance angle in LR group was 
9.6 +/- 5.0 (95% CI, 6.9 to 12.3). At 1 and 3 month after 
injection, it reduced significantly to 7.1+/-4.7(95% CI, 4.6 
to 9.6), and to 7.5+/- 4.9 (95% CI, 4.8 to 10.1) 
respectively, P=0.0086. The difference between the 
mean angle at 1 and 3 months after injection did not 
reach statistical significance (Table 1). The average 
preoperative near angle in LR group was 9.9+/- 5.2 (95% 
CI, 7.1 to12.7). At 1 month after injection, it reduced to 
7.6+/- 4.7, (95% CI, 4.8 to 10.3) and to 8.3+/- 5.1, (95% CI, 
5.4 to 11.2) at 3 months. These reductions did not reach 
statistical significance (Table 1). 
Out of 16 patients who had local anesthetic (LA) injection 
into their LR for esodeviation; 5 improved to the extent 
that patients were content and discharged, while 11 
required surgery. Among these 11 patients, five were 
better initially but not completely cured and therefore 
needed surgery while the other six did not change 
significantly. At 3 months, the angle of deviation 
improved to ≤10 PD for distance in 13 of 16(81%) and for 
near in 11 of 16(69%) compared to 8 of 16(50%) at pre-
op for distance and near. 
Fourteen patients (8 females and six males) with 
exotropia had one injection of BPX into their MR muscle, 
(right:7, left:7). Their average age was 43 (range: 20–60) 
years. 10/14 patients had previous surgery on their MR 
and were left with small angle residual exotropia. None 
had chemodenervation. The average preoperative 
distance angle in MR group was 7.9 +/- 5.1(95% CI, 4.9 to 
10.9). At 1 and 3 months after injection, it reduced to 
5.9+/-4.0 (95% CI, 2.8 to 8.9), and to 6.2+/- 4.7 (95% CI, 
2.8 to 9.6), p>0.05(Table 1). The average preoperative 
near angle in MR group was 11.3+/- 4.9, (95% CI, 8.3 to 
14.3). At 1 and 3 months after injection, it was reduced 
to 7.1+/- 5.5 (95% CI, 2.9 to 11.3) and 8.6+/- 6.8, 
respectively (95% CI, 4.5 to 12.7), P=0.06 (Table 1). Out of 
14 patients who had LA injection into their MR, 6 were 
improved to the extent that patients were contented and 
discharged, 4 had successful surgery, 2 were lost to 
follow-up, 1 is managed with prism and one did not want 
further intervention. At 3 months, the angle of deviation 
improved to ≤10 PD for distance in 11 of 14(74%) 
compared to 10 of 14 (71%) preoperatively and for near 
in 8 of 14(57%) compared to 6of 14 (43%) before the 
injection. 
The overall pre-op angle of deviation for distance was 
8.8+/- 5.1 (95% CI, 6.9 to 10.7), reduced to 6.5+/- 4.4 
(95% CI, 5.0 to 8.7) at 1 month and to 6.9+/-4.3(95% CI, 
5.2 to 9.1) at 3 month, p=0.02(Table 1). The overall pre-
op angle of deviation for near was 10.5+/- 5.1 (95% CI, 
8.5 to 12.4) and reduced to 7.4+/- 4.9 (95% CI, 5.3 to 9.5), 
or 8.4+/-5.8(95% CI, 6.2 to 10.7) at 1 and 3 months, 
respectively (Table 1). 
The mean improvements between eso- and exotropia 
groups were not significantly different. Eleven out of 
thirty patients achieved an acceptable angle with a single 
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injection of BPX that no further intervention was 
necessary. There were no complications. There was no 
significant correlation between pre-op angle and the 
change in the angle of deviation in any group. 
 
DISCUSSION 
Pharmacologic treatment of strabismus is an exciting and 
evolving field. This study represents the outcome of BPX 
injection in the management of a heterogeneous group 
of patients with small angle horizontal strabismus. 
The overall reduction in the angle of deviation decreased 
during four months of follow-up with clinical success rate 
of 37%. The largest reduction occurred in the 
exodeviation group one month after the injection of the 
MR muscle.  
Miller et al have recently shown a reduction of 4.7 PD at 
11.3 months after a single injection of BPX with stability 
of alignment changes up to 3 years (10). All their 
measurements were at 3 meters and therefore are not 
directly comparable with our results. 
Earlier Scott et al showed an average reduction of 8 PD 
with BPX alone and 19.7 PD reduction when combined 
with botulinum type A toxin into the antagonist (6–8). 
Wutthipan et al assessed 20 patients (14 exodeviations, 6 
esodeviations) at 1, 3, 6 and 12 months after BPX 
injection (11). Majority of their patients had an angle of 
deviation greater than 25PD. They noticed an 
improvement in 15 of 20 patients though not statistically 
significant. They also did not specify the distance of 
measurements. 
Our results support others’ findings as over one-third of 
our patients achieved satisfactory outcome after one 
injection. However, the success rate and the overall 
improvement are more modest than in the other groups. 
This may be due to the selection of patients with 
deviations less than 20PD or due to the difference the 
angle of deviations were measured and reported. 
Namely, these measurements in our study were 
performed at both 1/3 and 6 meters fixation targets. 
Scott et al also used a higher concentration of BPX 
(0.75% -3%) and higher volume compared to us (7). So, 
other options were offered to those who failed to 
achieve satisfactory outcome after one injection of BPX. 
It is well recognized that LR plays a more significant role 
in distance deviation and MR in near deviation. 
Therefore, we are of the opinion that simply reporting 
the angle of deviation for 3 meters should be avoided. 
When measuring small angle deviations, difficulty exists 
to establish whether the small changes represent a true 
change or are simply measurement error. Holmes et al 
have shown that interobserver test-retest reliability for 
alternate prism cover test can be as large as 10PD (12). 
Miller et al validated their measurement technique and 
showed good inter-observer reliability (10). We could not 
do the same due to the retrospective nature of our 
study. 
Interestingly, Miller et al have reported on long-term 
stability of changes achieved (up to 3 years), although 
they had limited number of patients with 8, 6 and 3 
patients after 1, 2 and 3 years (10). 
Increase in the mean angle of deviation at 3 months 
compared to 1 month, did not reach statistical 
significance. On the other hand, none of our 11 patients 
that were discharged with satisfactory outcome at 3 
month have come back with a recurrence after a 
minimum of 8 months following injection. There is of 
course the slim possibility that they have sought 
treatment elsewhere. 
Since BPX is, apparently, not effective in chronically 
denervated muscles, Miller et al excluded paralytic 
strabismus from their analysis (10). We also did not find 
encouraging results in two patients with partial recovery 
from abducens nerve palsy palsy. One with left LR palsy 
due to multiple sclerosis with primary esodeviation of 
6PD for near and 8PD for distance got better at 1 month 
(near 4PD, distance 2PD), but reverted to the initial 
angles at 3 months and underwent surgery. The other 
with ischemic left LR palsy and primary esotropia of 14PD 
for near and 18PD for distance did not change after 
injection and required surgery. When we excluded these 
patients, our results did not significantly change. 
As any other retrospective study, ours is burdened with 
some classical limitations, such as: relatively small 
number of cases, which may explain the lack of statistical 
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significance. Despite this, we believe that these results 
are helpful to the individual cases in clinical practice. 
Therefore, we believe we should continue to inform our 
patients of the 37% success rate when counseling. 
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